Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$189.50 -0.7%	$187.30	$163.63 ▼ $218.66	$336.94B	0.48	6.25 million shs	3.71 million shs
ALNY Alnylam Pharmaceuticals	$331.94 +0.7%	$293.35	$205.87 ▼ $333.70	$43.00B	0.23	853,986 shs	431,157 shs
BIIB Biogen	$132.63 -0.4%	$126.65	$110.04 ▼ $238.00	$19.52B	0.14	1.43 million shs	633,328 shs
INCY Incyte	$68.46 +0.4%	$65.34	$53.56 ▼ $83.95	$13.20B	0.68	1.97 million shs	1.27 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.67%	+1.30%	+1.24%	+1.57%	+15.66%
ALNY Alnylam Pharmaceuticals	+0.66%	+4.30%	+9.27%	+40.81%	+33.48%
BIIB Biogen	-0.42%	+4.49%	+0.60%	+7.84%	-40.95%
INCY Incyte	+0.43%	-3.32%	+2.01%	+13.01%	+18.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9057 of 5 stars	3.4	5.0	3.3	3.9	2.8	1.7	1.3
ALNY Alnylam Pharmaceuticals	4.3111 of 5 stars	2.4	4.0	0.0	4.3	3.9	2.5	0.6
BIIB Biogen	4.9439 of 5 stars	4.2	5.0	0.0	3.7	3.8	1.7	1.9
INCY Incyte	4.3987 of 5 stars	2.1	3.0	0.0	3.1	2.5	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	11.50% Upside
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$340.00	2.43% Upside
BIIB Biogen	2.38	Hold	$188.48	42.12% Upside
INCY Incyte	2.22	Hold	$74.53	8.87% Upside

Current Analyst Ratings Breakdown

Latest INCY, ABBV, ALNY, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/23/2025	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$67.00
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.94	$14.84 per share	12.77	$1.90 per share	99.74
ALNY Alnylam Pharmaceuticals	$2.25B	19.25	N/A	N/A	$0.52 per share	638.35
BIIB Biogen	$9.68B	2.01	$23.03 per share	5.76	$114.71 per share	1.16
INCY Incyte	$4.24B	3.12	$0.56 per share	123.14	$17.90 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	80.64	13.56	1.27	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	372.97	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	13.09	8.03	1.06	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.94	10.47	0.57	0.48%	2.77%	1.77%	7/29/2025 (Estimated)

Latest INCY, ABBV, ALNY, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	INCY Incyte	$1.38	N/A	N/A	N/A	$1.15 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.46%	N/A	279.15%	53 Years
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A

Latest INCY, ABBV, ALNY, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BIIB Biogen	0.27	1.44	1.01
INCY Incyte	0.01	2.04	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
ALNY Alnylam Pharmaceuticals	1.50%
BIIB Biogen	0.18%
INCY Incyte	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable

INCY, ABBV, ALNY, and BIIB Headlines

Recent News About These Companies

Incyte Corporation Advances Ruxolitinib Cream Study for Atopic Dermatitis

July 3 at 1:14 PM | tipranks.com

Incyte’s Phase 1 Study on INCB057643: A Potential Game-Changer for Myelofibrosis Treatment?

July 3 at 1:14 PM | tipranks.com

Incyte’s Phase 2 Study on INCB099280: A Potential Breakthrough in Skin Cancer Treatment

July 3 at 12:20 PM | tipranks.com

Incyte’s Phase 3 Study Update: Potential Market Impact for HNSCC Treatment

July 3 at 12:20 PM | tipranks.com

Incyte’s Ruxolitinib Cream Study: A Closer Look at Maternal and Infant Outcomes

July 3 at 12:20 PM | tipranks.com

Incyte: New CEO Brings A New Possible Outcome

July 3 at 6:37 AM | seekingalpha.com

Incyte’s Future Hinges on Pipeline Potential Amid Jakafi Exclusivity Loss

July 3 at 6:37 AM | tipranks.com

Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)

July 3 at 4:24 AM | marketbeat.com

Incyte Corp (INCY) Announces Equity Inducement Awards for New CEO Bill Meury | INCY stock news

July 2 at 6:13 PM | gurufocus.com

Incyte’s Promising Phase 1/2 Study: A New Hope for Advanced Solid Tumors

July 2 at 12:41 PM | tipranks.com

Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0

July 2 at 2:57 AM | benzinga.com

Incyte’s Phase 1 Study on INCB057643: A Potential Game-Changer in Myelofibrosis Treatment?

July 1 at 12:34 PM | tipranks.com

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

July 1 at 10:36 AM | zacks.com

CHURCHILL MANAGEMENT Corp Increases Stock Holdings in Incyte Corporation (NASDAQ:INCY)

July 1 at 6:29 AM | marketbeat.com

Bessemer Group Inc. Sells 32,765 Shares of Incyte Corporation (NASDAQ:INCY)

July 1 at 3:56 AM | marketbeat.com

Incyte’s Ongoing Rollover Study of Povorcitinib: Key Insights for Investors

June 30, 2025 | tipranks.com

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”

June 30, 2025 | insidermonkey.com

Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”

June 30, 2025 | finance.yahoo.com

KBC Group NV Reduces Stock Position in Incyte Corporation (NASDAQ:INCY)

June 30, 2025 | marketbeat.com

23,678 Shares in Incyte Corporation (NASDAQ:INCY) Acquired by Sovran Advisors LLC

June 30, 2025 | marketbeat.com

Illinois Municipal Retirement Fund Reduces Holdings in Incyte Corporation (NASDAQ:INCY)

June 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY, ABBV, ALNY, and BIIB Company Descriptions

AbbVie NYSE:ABBV

$189.50 -1.25 (-0.66%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$188.90 -0.60 (-0.32%)

As of 07/3/2025 04:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Alnylam Pharmaceuticals NASDAQ:ALNY

$331.94 +2.17 (+0.66%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$331.94 0.00 (0.00%)

As of 07/3/2025 04:05 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$132.62 -0.57 (-0.42%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$132.87 +0.25 (+0.18%)

As of 07/3/2025 04:57 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$68.46 +0.29 (+0.43%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$67.23 -1.23 (-1.80%)

As of 07/3/2025 04:18 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time